Open Orphan Plc (LON:ORPH) said it has signed five unnamed pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform that is planned for launch in the first quarter of next year.
They will ensure it is “fit-for-purpose” ahead of the first patient upload.
This builds on the previously-announced collaboration with Empiric Logic, which is working with Open Orphan to complete the product.
"We are very excited to be working with these leading pharmaceutical and biotechnology companies on our market leading DataBANK. The Genomic Health DataBANK, which makes extensive use of AI tools, is an innovative research tool for pharmaceutical companies, and we are excited by its potential when launched in early 2020,” said Open Orphan chief commercial officer, Maurice Treacy.
“We believe the DataBANK can ignite research for new diagnostic tools and therapeutic products for rare disease patients."
Collaborations are also underway with patient advocacy groups to make sure potential users are aware of the service.
Open Orphan has two data-driven digital platforms: The aforementioned Genomic Health DataBANK, which is creating a rare disease database, and its Virtual Rep product, which enables pharmaceutical companies to engage key opinion leaders and doctors.